Parameter
| Biomarker | miR-21 (microrNA-21) | Full name | microRNA-21 | Molecular Type | Non-coding RNA (microRNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis and prediction | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Test Sample / Technology Platform | Serum (qPCR, digital PCR), tumor tissue (qPCR, in situ hybridization) | |||
| Pathobiological Mechanisms | Carcinogenic microRNA, miR-21 is highly expressed in gastric cancer tissues and serum, which can promote tumor proliferation, invasion and chemotherapy resistance by targeting tumor suppressor genes such as PTEN and PDCD4 and activating PI3K/Akt pathway. Patients with high expression of Mir-21 have poor prognosis | ||||
| Clinical Availability Status | Basic research/early clinical: a large number of basic studies have confirmed its diagnostic and prognostic value, and clinical validation in small samples shows that the diagnostic sensitivity is about 75%, which needs large-scale validation | ||||
| Notes and Dynamics | As a potential non-invasive marker for early diagnosis of gastric cancer, serum miR-21 detection is convenient and minimally invasive, and can be used for high-risk population screening. Combined with other mirnas (such as miR-375 and miR-148a), the diagnostic accuracy can be improved. Antisense oligonucleotide (ASO) targeting miR-21 is a potential therapeutic strategy | ||||